Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vaccinium myrtillus extract + aronia melanocarpa extract + lonicera caerulea extract
- Development stage
- Unknown
- Lead developer
- Greenvit
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
OCULOXIN is a standardized botanical dietary supplement complex developed by the Polish company Greenvit. It contains a specific 2:1:1 ratio of extracts from bilberry (Vaccinium myrtillus), chokeberry (Aronia melanocarpa), and honeysuckle berry (Lonicera caerulea). The formulation is standardized to contain at least 25% anthocyanins and 4.5% iridoids, which are polyphenolic compounds known for their antioxidant and anti-inflammatory properties. OCULOXIN is primarily targeted at supporting visual health, with clinical studies demonstrating its efficacy in improving near visual acuity and contrast sensitivity in individuals with presbyopia. It is also investigated for its potential benefits in addressing digital eye strain, eye fatigue (asthenopia), and early-stage diabetic retinopathy.
- Brand names
- OCULOXIN
- Other names
- AKB complexbilberry extract + chokeberry extract + honeysuckle berry extract
Beyond the preview
Go deeper on vaccinium myrtillus extract + aronia melanocarpa extract + lonicera caerulea extract.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vaccinium myrtillus extract + aronia melanocarpa extract + lonicera caerulea extract.